Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity

Thrombosis and Haemostasis

Volumn 94, Issue 5, 2005, Pages 1084-1093

  Banke, Ingo J ^a   Arlt, Matthias J E ^a   Mueller, Markus M ^b   Sperl, Stefan ^c   Stemberger, Axel ^a   Stürzebecher, Jörg ^d   Amirkhosravi, Ali ^e   Moroder, Luis ^b   Krüger, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c Wilex Biotechnology GmbH   (Germany)

^d Klinikum der Universitat Jena   (Germany)

^e FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

Author keywords

Coagulation factor Xa inhibitor; Fibrosarcoma; Lymphoma; Metastasis

Indexed keywords

2 (3 ADAMANTAN 1 YL UREIDO) 3 (3 CARBAMIMIDOLYPHENYL) N PHENETHYLPROPIONAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WX FX 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; DRUG STRUCTURE; FIBROSARCOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; T CELL LYMPHOMA;

ADAMANTANE; ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; FACTOR XA; FEMALE; FIBROSARCOMA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOMA, T-CELL; MICE; MICE, INBRED DBA; NAPHTHALENES; PROPIONIC ACIDS; SERINE PROTEINASE INHIBITORS; SPECIFIC PATHOGEN-FREE ORGANISMS; WHOLE BLOOD COAGULATION TIME;

EID: 27844610322     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-04-0249     Document Type: Article

References (51)

1. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998; 24: 93-109.
2. Zacharski LR. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost 2003; 29: 239-46.
3. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15: 61-7.
4. Bura A, Cailleux N, Bienvenu B et al. Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. J Thromb Haemost 2004; 2: 441-4.
5. Sallah S, Wan JY, Nguyen NP et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86: 828-33.
6. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-96.
7. Wicki J, Perrier A, Perneger TV et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-52.
8. Hembrough TA, Swartz GM, Papathanassiu A et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
9. Palumbo JS, Kombrinck KW, Drew AF et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
10. Hu L, Lee M, Campbell W et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104: 2746-51.
11. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002; 30: 201-7.
12. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36.
13. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.
14. Ornstein DL, Zacharski LR. Activity of heparins in experimental models of malignancy: Possible explanations for anticancer effects in humans. Clin Hemorheol Microcirc 2002; 26: 33-40.
15. Amirkhosravi A, Mousa SA, Amaya M et al. Anti-metastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 1972-6.
16. Francis JL, Carty N, Amirkhosravi M, et al. The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding. Br J Cancer 1992; 65: 329-34.
17. Amirkhosravi M, Francis JL. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation. Thromb Haemost 1995; 73: 59-65.
18. Leadley RJ Jr., Chi L, Porcari AR. Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol 2001;1:169-75.
19. Jiang X, Bailly MA, Panetti TS et al. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004; 2: 93-101.
20. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-23.
21. Donnelly KM, Bromberg ME, Milstone A etal. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998; 79: 1041-7.
22. Banke IJ, Arlt MJ, Pennington C et al. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors. Biol Chem 2003; 384: 1515-25.
23. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Des 2003; 9: 2337-47.
24. Krüger A, Soeltl R, Sopov I et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001; 61: 1272-5.
25. Arlt M, Kopitz C, Pennington C et al. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 2002; 62: 5543-50.
26. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
27. Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem 2002; 38: 95-111.
28. Drew AF, Kaufman AH, Kombrinck KW et al. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998; 91: 1616-24.
29. Neurath H. Proteolytic enzymes, past and future. Proc Natl Acad Sci U S A 1999; 96: 10962-3.
30. Yoshida S, Shiosaka S. Plasticity-related serine proteases in the brain (review). Int J Mol Med 1999; 3: 405-9.
31. Mueller MM, Sperl S, Stürzebecher J et al. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode. Biol Chem 2002;383:1185-91.
32. Krüger A, Umansky V, Rocha M et al. Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma. Blood 1994; 84: 3166-74.
33. Krüger A, Schirrmacher V, Khokha R. The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev 1998; 17: 285-94.
34. Nagahara T, Yokoyama Y, Inamura K, et al. Dibasic (amidinoaryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994; 37: 1200-7.
35. Stürzebecher J, Prasa D, Hauptmann J et al. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinopheny-lalanine. J Med Chem 1997; 40: 3091-9.
36. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-1.
37. Hauptmann J, Steinmetzer T, Vieweg H et al. Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats. Pharm Res 2002; 19: 1027-33.
38. Schweinitz A, Steinmetzer T, Banke IJ et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613-22.
39. Sinha U, Lin PH, Edwards ST et al. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors. Arterioscler Thromb Vasc Biol 2003; 23: 1098-104.
40. Deitcher SR. Clinical utility of subcutaneous hirudins. Am J Health Syst Pharm 2003; 60 Suppl 5: S27-31.
41. Mann KG, Nesheim ME, Church WR et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
42. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-21.
43. Kaiser B. DX-9065a, a direct inhibitor of factor Xa. Cardiovasc Drug Rev 2003; 21: 91-104.
44. Amirkhosravi A, Mousa SA, Amaya M et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90: 549-54.
45. Camerer E, Qazi AA, Duong DN et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
46. Palumbo JS, Talmage KE, Massari JV et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-85.
47. Camerer E, Huang W Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 2000; 97: 5255-60.
48. McCulloch P George WD. Warfarin inhibition of metastasis: the role of anticoagulation. Br J Surg 1987; 74: 879-83.
49. Koop S, Schmidt EE, MacDonald IC et al. Independence of metastatic ability and extravasation: metastatic ras- transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci U S A 1996; 93: 11080-4.
50. Naumov GN, Wilson SM, MacDonald IC et al. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci 1999; 112: 1835-42.
51. DeClerck YA, Imren S, Montgomery AM et al. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997; 425: 89-97.